Browse Categories

Publications by authors named "Gabriela Sanz"

  • Page 1 of 1
Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.
Lourdes Farre Gabriela Sanz Neus Ruiz-Xivillé Manuel Castro de Moura Juan Francisco Martin-Tejera

Dis Model Mech

July 2021

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. Besides, well-characterized preclinical models for EMM are not available.

View Article and Find Full Text PDF
Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma.
Clara Maluquer Beatriz Bellosillo Alberto Mussetti Eva Domingo-Domènech Rocío Parody Gabriela Sanz

EJHaem

February 2021

Objectives: Chimeric antigen receptor T cells (CARTs) against CD19 antigen represent an effective therapy for relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL). There is no diagnostic test able to predict which patients with residual disease will relapse from those that will reach a delayed complete response. Positron emission tomography/computed tomography scan (PET-CT) is characterized by a significant number of false positive results after immunotherapy.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Gabriela Sanz"

  • - Gabriela Sanz's research primarily focuses on the genetic mechanisms and therapeutic strategies associated with hematological malignancies, specifically extramedullary multiple myeloma and diffuse large B-cell lymphoma.
  • - In her work, Sanz emphasizes the need for better preclinical models and diagnostic tools, revealing that current methods for monitoring disease can yield misleading results, particularly in cases following CAR-T cell therapy.
  • - Her studies highlight the challenges faced in predicting patient outcomes and improve treatment efficacy, advocating for the development of novel therapeutic interventions and liquid biopsy approaches for more accurate disease monitoring.

Privacy Policy Site Map

© LitMetric 2025. All rights reserved.